WASHINGTON, D.C. – The Sabin Vaccine Institute (Sabin) is pleased to announce the election of Wendy Commins Holman to its Board of Trustees. Ms. Holman is the CEO and founder of Ridgeback Biotherapeutics, a biotechnology company focused on developing treatments and diagnostics for underserved patient populations primarily in pediatric orphan and emerging infectious diseases.
Statements and Press Releases
WASHINGTON, D.C. – April 25, 2017 – Tonight, the Sabin Vaccine Institute (Sabin) will honor Dr. Jan Holmgren with the 2017 Albert B. Sabin Gold Medal Award. Dr. Holmgren will be recognized for his pioneering contributions to oral vaccine research and mucosal immunology, as well as his leadership in the discovery of the world's first effective oral cholera vaccine.
KAMPALA, UGANDA – April 4, 2017 – Today, the Sabin Vaccine Institute opened the 10th International Conference on Typhoid and Other Invasive Salmonelloses in Kampala, Uganda. Over the course of the three day conference, more than 300 experts from around the world have gathered to discuss new typhoid-related research, as well as how to turn this evidence into action in the fight against typhoid.
TBILISI, GEORGIA — March 1, 2017 — Today, the Sabin Vaccine Institute and the Government of Georgia assembled senior officials from Armenia, Georgia and Moldova to develop legislative roadmaps that will support the sustainability of national immunization programs to protect more than 16.6 million people.